Clinical Trial Update: A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for MRG002 in HER2-mutated unresectable/metastatic non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MRG002

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Non-small- Cell Lung Cancer (NSCLC) | Phase 2 | Status: UNKNOWN